Sage Journals: Discover world-class research

Abstract

Background:

Multiple sclerosis (MS) prevalence is increasing globally.

Objectives:

To determine whether increased prevalence is continuing within Australia using our validated prescription-based ascertainment method.

Methods:

We used methods employed in our 2010 and 2017 prevalence estimates. Disease-modifying therapy (DMT) prescriptions were extracted from Australia’s Pharmaceutical Benefits Scheme data for January–December 2021. DMT penetrance was calculated using data from the Australian MS Longitudinal Study. We divided the total number of monthly prescriptions by 12 or 2 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates. Prevalences in Australian states/territories were age-standardised. 2021 prevalence estimates were compared with 2010 and 2017 prevalence estimates using Poisson regression.

Results:

Number of people with MS in Australia in 2021 was 33,335; an increase of 7728 from 2017 (30.2%) and 12,092 from 2010 (56.6%) and increasing at a faster rate than population change (+10.1%, +14.1%). Age-standardised prevalence was 136.1/100,000 (increased from 103.7/100,000 in 2017). The previously demonstrated positive latitudinal gradient in 2010 and 2017 persisted in 2021, with Tasmania (southernmost state) having the highest prevalence (age-standardised: 203.5/100,000) while northernmost states had the lowest.

Conclusions:

In line with global trends, MS prevalence is escalating in Australia, particularly in higher-latitude states. MS prevention is crucial to halt this disturbing trend.

Keywords

Multiple sclerosis MS MS disease-modifying therapies epidemiology MS prevalence DMT penetrance latitude

Get full access to this article

View all access options for this article.

References

Campbell

van der Mei

Taylor

, et al. Health economic impact of MS in 2021: An interim update of prevalence, costs and costs of illness from 2017 to 2021. North Sydney, NSW, Australia: Multiple Sclerosis Australia, 2023, https://www.msaustralia.org.au/wp-content/uploads/2023/02/health-economic-impact-of-multiple-sclerosis-in-australia-in-2021_final.pdf

Taylor

. What causes multiple sclerosis? Getting closer to the answers. Med J Aust 2022; 217(4): 180–182.

Walton

King

Rechtman

, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler 2020; 26(14): 1816–1821.

Multiple Sclerosis International Federation. Atlas of multiple sclerosis, 2022, https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf

Nelson

Wallin

Marrie

, et al. A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS. Neurology 2019; 92(10): 469–480.

Wallin

Culpepper

Campbell

, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology 2019; 92(10): e1029–e1040.

Briggs

Hill

. Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States. Mult Scler 2020; 26(14): 1948–1952.

Wnuk

Maluchnik

Perwieniec

, et al. Multiple sclerosis incidence and prevalence in Poland: Data from administrative health claims. Multi Scler Relat Dis 2021; 55: 103162.

Palmer

Colman

O’Leary

, et al. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler 2013; 19(12): 1640–1646.

10.

Campbell

Simpson

Jr Ahmad

, et al. Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data. Mult Scler 2020; 26(11): 1315–1328.

11.

Ahmad

Campbell

van der Mei

, et al. Health Economic Impact of Multiple Sclerosis in Australia in 2017: An analysis of MS Research Australia’s platform – The Australian MS Longitudinal Study (AMSLS). North Sydney, NSW, Australia: Multiple Sclerosis Australia, 2018. https://www.msaustralia.org.au/wp-content/uploads/2018/08/health-economic-impact-of-ms-in-australia-in-2017_ms-research-australia_web.pdf

12.

Culyer

. The dictionary of health economics. Cheltenham: Edward Elgar Publishing, 2010.

13.

Culyer

. Encyclopedia of health economics. New York: Elsevier, 2014.

14.

Zhao

Taylor

Campbell

, et al. The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022. Mult Scler 2024; 30(1): 80–88.

15.

Australian Government. 2021-22 federal budget. Canberra, ACT, Australia: Treasury, 2021, https://wwwfinancegovau/about-us/news/2021/2021-22-federal-budge

16.

Australian Government. Pharmaceutical benefits schedule item reports, http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp

17.

Zhang

Taylor

Simpson

Jr , et al. Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype. Mult Scler 2021; 27(8): 1262–1275.

18.

Van Dijk

Kirk-Brown

Taylor

, et al. Closing the gap: Longitudinal changes in employment for Australians with multiple sclerosis. Mult Scler 2017; 23(10): 1415–1423.

19.

Australian Bureau of Statistics. Australian Bureau of Statistics: Census population data, 2021. https://www.abs.gov.au/statistics/people/population/2021-census-overcount-and-undercount/2021

20.

Australian Bureau of Statistics. 3101.0 – Australian demographic statistics, Sep 2017, 2017, http://www.abs.gov.au/AUSSTATS/abs@.nsf/allprimarymainfeatures/819D0CD114A1BACFCA2582B20017D835?opendocument

21.

Breslow

Day

Heseltine

. Statistical methods in cancer research. Lyon: IARC Publications, 1980.

22.

Walton

King

Rechtman

, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler 2020; 26(14): 1816–1821.

23.

Simpson-Yap

Atvars

Blizzard

, et al. Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia. J Neurol Neurosurg Psychiatry. Epub ahead of print 16 May 2022. DOI: 10.1136/jnnp-2022-328932

24.

Simpson-Yap

Maddox

Reece

, et al. Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022. Mult Scler Relat Disord 2023; 77: 104845.

25.

Steinmetz

Seeher

Schiess

, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024; 23(4): 344–381.

26.

Chen

Campbell

Bardsley

, et al. MS Nurse Care in Australia: Patterns of access and impact on health outcomes. Blackburn, VIC, Australia: MS Australia, 2022, https://www.msaustralia.org.au/wp-content/uploads/2022/04/msa_ms-nurses-report_web.pdf

27.

Solomon

Marrie

Viswanathan

, et al. Global barriers to the diagnosis of multiple sclerosis: Data from the multiple sclerosis international federation atlas of MS. Neurology 2023; 101(6): e624–e635.

28.

Simpson

Jr Blizzard

Otahal

, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: A meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82(10): 1132–1141.

29.

Simpson

Jr Wang

Otahal

, et al. Latitude continues to be significantly associated with the prevalence of multiple sclerosis: An updated meta-analysis. J Neurol Neurosurg Psychiatry 2019; 90(11): 1193–1200.

30.

Sharmin

Roos

Simpson-Yap

, et al. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Brain 2023; 146(11): 4633–4644.

31.

Taylor

Pearson

Clarke

, et al. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler 2010; 16(12): 1422–1431.

32.

Sabel

Pearson

Mason

, et al. The latitude gradient for multiple sclerosis prevalence is established in the early life course. Brain 2021; 144(7): 2038–2046.

33.

Lonergan

Kinsella

Fitzpatrick

, et al. Multiple sclerosis prevalence in Ireland: Relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 2011; 82(3): 317–322.

34.

French

Simpson-Yap

van der Mei

, et al. Identification of a latitude gradient in the prevalence of primary biliary cholangitis. Clin Transl Gastroenterol 2021; 12(5): e00357.

35.

McGuigan

McCarthy

Quigley

, et al. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry 2004; 75(4): 572–576.

36.

Disanto

Pakpoor

Morahan

, et al. Epstein-Barr virus, latitude and multiple sclerosis. Mult Scler 2013; 19(3): 362–365.

37.

O’Gorman

Broadley

. Smoking and multiple sclerosis: Evidence for latitudinal and temporal variation. J Neurol 2014; 261(9): 1677–1683.

38.

Ramagopalan

Handel

Giovannoni

, et al. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011; 76(16): 1410–1414.

39.

Jokubaitis

Spelman

Lechner-Scott

, et al. The Australian Multiple Sclerosis (MS) immunotherapy study: A prospective, multicentre study of drug utilisation using the MSBase platform. PLoS ONE 2013; 8(3): e59694.

40.

Hillert

Magyari

Soelberg Sørensen

, et al. Treatment switching and discontinuation over 20 years in the big multiple sclerosis data network. Front Neurol 2021; 12: 647811.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021

Abstract

Background:

Objectives:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References

Supplementary Material